Clinical Research Directory
Browse clinical research sites, groups, and studies.
Biomarker Signature-Supported Antibiotic Treatment Decisions in ICU
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Summary
The goal of this randomized clinical trial is to determine whether a biomarker-signature (BV) supported antibiotic treatment decision matrix can have a beneficial impact on antibiotic use and patient outcomes in an ICU population.
Official title: Biomarker Signature-Supported Antibiotic Treatment Decisions in Intensive Care Units
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
1200
Start Date
2025-05-13
Completion Date
2028-08
Last Updated
2026-03-19
Healthy Volunteers
No
Conditions
Interventions
Biomarker-signature supported antibiotic treatment recommendation
The antibiotic treatment recommendation will be based on a decision matrix that combines the results of the BV-signature (a score ranging from 0 -100) with the clinical assessment of likelihood of bacterial infection.
Clinical assessment for antibiotic treatment decision
Antibiotic treatment decision will be based on clinical assessment only (BV test result remains masked)
Locations (4)
Montreal General Hospital
Montreal, Quebec, Canada
Research Institute of McGill University Health Center (RI-MUHC)
Montreal, Quebec, Canada
Royal Victoria Hospital
Montreal, Quebec, Canada
Research Institute McGill University Health Centre
Montreal, Quebec, Canada